This week in MathOnco: 143
Cancer milestones; plasticity; liquid biopsies; cancer risk; CAR T-cells
“This week in Mathematical Oncology” — Newsletter
Dec. 31, 2020
>
jeffrey.west@moffitt.org
>
From the editor:
Dear readers,
This week’s edition includes articles on cancer milestones, plasticity, liquid biopsies, cancer risk, and one of my own publications, too (Isomatrix!).
During the break, I had an opportunity to catch up on some reading. I highly recommend picking up a copy of “
Apollo’s Arrow
” — an engaging treatise on the public health implications of coronavirus (and pandemics more generally). It’s complete with a nice overview of epidemiological models and intuition. Pick up your copy
here
.
-Jeffrey West
Milestones in cancer
NatureIsoMaTrix: a framework to visualize the isoclines of matrix games and quantify uncertainty in structured populations
Jeffrey West, Yongqian Ma, Artem Kaznatcheev, Alexander R A AndersonNext-Generation Liquid Biopsies: Embracing Data Science in Oncology
Y.R. Im, D.W.Y. Tsui, L.A. Diaz Jr, J.C.M. WanSelection-driven tumor evolution involving non-cell growth promotion leads to patterns of clonal expansion consistent with neutrality interpretation
Jack Edwards, Andriy Marusyk, David BasantaDeep learning-based cross-classifications reveal conserved spatial behaviors within tumor histological images
Javad Noorbakhsh, Saman Farahmand, Ali Foroughi pour, Sandeep Namburi, Dennis Caruana, David Rimm, Mohammad Soltanieh-ha, Kourosh Zarringhalam, Jeffrey H. ChuangA closed-loop optimization framework for personalized cancer therapy design
Fabrizio Angaroni; Mattia Pennati; Lucrezia Patruno; Davide Maspero; Marco Antoniotti; Alex GraudenziDetermining cancer risk: the evolutionary multistage model or total stem cell divisions?
Leonard Nunney and Kevin ThaiStepping From Modeling Cancer Plasticity to the Philosophy of Cancer
Jean ClairambaultAn optimal control approach for enhancing natural killer cells' secretion of cytolytic molecules
Sahak Z. Makaryan, Stacey D. Finley
Dual-Target Car-Ts With on- and off-Tumour Activity May Override Immune Suppression in Solid Cancers: A Mathematical Proof of Concept
Odelaisy León-Triana, Antonio Pérez-Martínez, Manuel Ramírez-Orellana, Víctor M. Pérez-GarcíaMathematical model of brain tumour growth with drug resistance
José Trobia, Kun Tian, Antonio Marcos Batista, Celso Grebogi, Hai-Peng Ren, Moises Souza Santos, Paulo Ricardo Protachevicz, Fernando da Silva Borges, José Danilo Szezech Jr, Ricardo Luiz Viana, Iberê Luiz Caldas, Kelly Cristiane IaroszMultistability and consequent phenotypic plasticity in AMPK-Akt double negative feedback loop in cancer cells
Adithya Chedere, Kishore Hari, Saurav Kumar, Annapoorni Rangarajan, Mohit Kumar JollyGARD is a pan-cancer predictor of clinical outcome in radiation treated patients
Jacob G. Scott, Geoffrey Sedor, Patrick Ellsworth, Jessica A. Scarborough, Kamran Ahmed, Steven A. Eschrich, Javier F. Torres-Roca, Michael W. Kattan
Evolutionary Therapy - Request for Application (RFA)
Anticancer Fund: Independent research fund focusing on cancer treatments
Knowledge about tumour evolutionary dynamics has been growing rapidly. However, there has been a limited translation of that knowledge into therapeutic trials. The most clinically advanced strategy is adaptive therapy. Adaptive therapy is a treatment strategy attempting to prolong response to treatment by delaying the emergence of resistance. The goal of adaptive therapy is to maintain a controllable stable tumour burden by allowing a significant population of treatment-sensitive cells to survive. The main principle of the intervention is to control the tumour and prolong survival by allowing on/off treatment periods based on a valid marker.
This RFA will accept clinical trials on adaptive therapy and any other evolutionarily informed strategy, as long as they meet all criteria (see eligibility criteria here).
Virtual Seminar: Mathematical and Computational Sciences Special Interest Group
Next talk: Heiko Enderling, Ph.D., H. Lee Moffitt Cancer Center & Research Institute.
Title: Calibrated, Validated and Predictive Mathematical Models for Clinical Oncology
Apollo's Arrow:
The Profound and Enduring Impact of Coronavirus on the Way We Live
N. Christakis: "Apollo's Arrow offers a riveting account of the impact of the coronavirus pandemic as it swept through American society in 2020, and of how the recovery will unfold in the coming years. Drawing on momentous (yet dimly remembered) historical epidemics, contemporary analyses, and cutting-edge research from a range of scientific disciplines, bestselling author, physician, sociologist, and public health expert Nicholas A. Christakis explores what it means to live in a time of plague — an experience that is paradoxically uncommon to the vast majority of humans who are alive, yet deeply fundamental to our species."
Understanding the Evolutionary Dynamics and Ecology of Cancer in Treatment Resistance
Guest Editor: David BasantaMathematical Models of Cellular Immunotherapies in Cancer
Guest Editors: V. Pérez-García, L. de Pillis, P. Altrock, R. RockneFrom Ecology to Cancer Biology and Back Again
Guest Editors: Fred Adler, Sarah Amend, Chris WhelanFrontiers in quantitative cancer modeling
Guest Editors: Mohit Kumar Jolly, Heiko Enderling
Postdoc in Statistics & Mathematics for Personalized Breast Cancer Therapy (Alvaro Köhn-Luque)
PhD on Modelling Cell Life and Death (Dan Tennant/Fabian Spill)
Mathematical Modeling Expert in Oncology Translational Science (Boehringer Ingelheim)
Research Associate - Biostatistician (University of Manchester)
Research Fellow in Computational Systems Biology Cancer Research (Simon Mitchell)
Research Fellow in Laboratory and Computational Systems Biology Cancer Research (Simon Mitchell)
Postdoctoral Fellow in Cancer Resistance Modeling, Pfizer (Blerta Shtylla)
Principal Scientist – Oncology PK/PD Modelling (Boehringer Ingelheim)
Postdoctoral Research Position in Computational Immunology (Sylvain Cussat-Blanc)
Postdoc Position - TKI treatments in lung cancer (David Basanta)
Systems Biology Modeler Positions in Biopharma Consulting Company (Helen Moore)
Computational Approaches to Breast Cancer Evolution - Postdoc (Marc Ryser)
Math/statistical models of stem cell lineage dynamics and cancer genomics - Postdoc (Adam MacLean)
Postdoctoral Research Position in Computational Oncology (Tom Yankeelov)
Current subscriber count: 844